UK Markets closed

Evgen Pharma plc (EVG.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
5.95-0.15 (-2.46%)
At close: 4:25PM BST

Evgen Pharma plc

Alderley Park, Block 24
Suite 24G13 Congleton Road
Nether Alderley SK10 4TG
United Kingdom
44 16 2546 6591

Full-time employees8

Key executives

NameTitlePayExercisedYear born
Dr. Huw JonesChief Exec. Officer224.4kN/A1960
Mr. Richard Anthony MoulsonCFO & Exec. Director107.28kN/A1962
Dr. Helen KuhlmanChief Bus. OfficerN/AN/AN/A
Dr. Glen Clack FFPM, M.D.Chief Medical OfficerN/AN/AN/A
Ms. Liz JenkinsRegulatory ConsultantN/AN/AN/A
Prof. Albena Dinkova-KostovaIndependent Scientific AdvisorN/AN/AN/A
Prof. Giovanni MannIndependent Scientific AdvisorN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections. Evgen Pharma plc was founded in 2007 and is headquartered in Nether Alderley, the United Kingdom.

Corporate governance

Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.